116 related articles for article (PubMed ID: 16770110)
1. [A case of hormone-refractory prostate cancer (HRPC) with tumor fever responding to docetaxel plus prednisolone therapy].
Miura N; Numata K; Azuma K; Hashine K; Sumiyoshi Y
Gan To Kagaku Ryoho; 2006 Jun; 33(6):841-4. PubMed ID: 16770110
[TBL] [Abstract][Full Text] [Related]
2. Docetaxel-prednisolone combination therapy for Japanese patients with hormone-refractory prostate cancer: a single institution experience.
Miura N; Numata K; Kusuhara Y; Shirato A; Hashine K; Sumiyoshi Y
Jpn J Clin Oncol; 2010 Nov; 40(11):1092-8. PubMed ID: 20587613
[TBL] [Abstract][Full Text] [Related]
3. [Combination chemotherapy with docetaxel and cisplatin in patients with hormone-refractory prostate cancer].
Fujinami K; Miura T; Takizawa A; Osada Y
Hinyokika Kiyo; 2005 Jan; 51(1):5-8. PubMed ID: 15732332
[TBL] [Abstract][Full Text] [Related]
4. Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: a multicenter Phase II trial in Japan.
Naito S; Tsukamoto T; Koga H; Harabayashi T; Sumiyoshi Y; Hoshi S; Akaza H
Jpn J Clin Oncol; 2008 May; 38(5):365-72. PubMed ID: 18417502
[TBL] [Abstract][Full Text] [Related]
5. Weekly administration of docetaxel in patients with hormone-refractory prostate cancer: a pilot study on Japanese patients.
Kojima T; Shimazui T; Onozawa M; Tsukamoto S; Hinotsu S; Miyanaga N; Hattori K; Kawai K; Akaza H
Jpn J Clin Oncol; 2004 Mar; 34(3):137-41. PubMed ID: 15078909
[TBL] [Abstract][Full Text] [Related]
6. Docetaxel and zoledronic acid in patients with metastatic hormone-refractory prostate cancer.
Vordos D; Paule B; Vacherot F; Allory Y; Salomon L; Hoznek A; Yiou R; Chopin D; Abbou CC; de la Taille A
BJU Int; 2004 Sep; 94(4):524-7. PubMed ID: 15329105
[TBL] [Abstract][Full Text] [Related]
7. [Successful treatment with docetaxel and prednisolone for paxlitaxel and carboplatin-resistant prostate cancer].
Kusukawa N; Ishida H; Tanase K; Ito H; Aoki Y; Ooyama N; Akino H; Yokoyama O
Hinyokika Kiyo; 2013 May; 59(5):301-4. PubMed ID: 23719139
[TBL] [Abstract][Full Text] [Related]
8. Treatment of androgen-independent, hormone-refractory prostate cancer with docetaxel in Japanese patients.
Miyoshi Y; Uemura H; Nakamura M; Hasumi H; Sugiura S; Makiyama K; Nakaigawa N; Kishida T; Ogawa T; Yao M; Kubota Y
Int J Clin Oncol; 2005 Jun; 10(3):182-6. PubMed ID: 15990966
[TBL] [Abstract][Full Text] [Related]
9. Biweekly administration of low-dose docetaxel in hormone-resistant prostate cancer: pilot study of an effective subtoxic therapy.
Karavasilis V; Briasoulis E; Siarabi O; Pavlidis N
Clin Prostate Cancer; 2003 Jun; 2(1):46-9. PubMed ID: 15046684
[TBL] [Abstract][Full Text] [Related]
10. [A case of hormone/docetaxel-refractory prostate cancer in which PSA level decreased after docetaxel+zoledronic acid treatment].
Okajima K; Yamashita Y; Onuki T; Fujinami K; Senga Y; Goto A; Jinza S; Asakura T
Gan To Kagaku Ryoho; 2008 Jul; 35(7):1247-9. PubMed ID: 18633274
[TBL] [Abstract][Full Text] [Related]
11. Real-world uptake, safety profile and outcomes of docetaxel in newly diagnosed metastatic prostate cancer.
Rulach RJ; McKay S; Neilson S; White L; Wallace J; Carruthers R; Lamb C; Cascales A; Marashi H; Glen H; Venugopal B; Sadoyze A; Sidek N; Russell JM; Alhasso A; Dodds D; Laskey J; Jones RJ; MacLeod N
BJU Int; 2018 Feb; 121(2):268-274. PubMed ID: 28940952
[TBL] [Abstract][Full Text] [Related]
12. First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter?
Michels J; Montemurro T; Murray N; Kollmannsberger C; Nguyen Chi K
Cancer; 2006 Mar; 106(5):1041-6. PubMed ID: 16456811
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of androgen-independent hormone refractory prostate cancer using docetaxel].
Miyoshi Y; Uemura H; Kubota Y
Nihon Rinsho; 2005 Feb; 63(2):298-302. PubMed ID: 15714982
[TBL] [Abstract][Full Text] [Related]
14. A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer.
Collins R; Trowman R; Norman G; Light K; Birtle A; Fenwick E; Palmer S; Riemsma R
Br J Cancer; 2006 Aug; 95(4):457-62. PubMed ID: 16880788
[TBL] [Abstract][Full Text] [Related]
15. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S
Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
[TBL] [Abstract][Full Text] [Related]
16. The preliminary results of docetaxel-prednisolone combination therapy for the Japanese patients with hormone-refractory prostate cancer.
Numata K; Miura N; Azuma K; Hashine K; Sumiyoshi Y
Hinyokika Kiyo; 2007 Feb; 53(2):93-7. PubMed ID: 17352157
[TBL] [Abstract][Full Text] [Related]
17. An open-label, noncomparative phase II trial to evaluate the efficacy and safety of docetaxel in combination with gefitinib in patients with hormone-refractory metastatic prostate cancer.
Salzberg M; Rochlitz C; Morant R; Thalmann G; Pedrazzini A; Roggero E; Schönenberger A; Knuth A; Borner M
Onkologie; 2007 Jul; 30(7):355-60. PubMed ID: 17596743
[TBL] [Abstract][Full Text] [Related]
18. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of taxotere, thalidomide, and prednisolone in patients with hormone-resistant metastatic prostate cancer.
Rezvani H; Haghighi S; Ghadyani M; Attarian H
Urol J; 2012; 9(4):673-7. PubMed ID: 23235972
[TBL] [Abstract][Full Text] [Related]
20. [Toxicity and efficacy of intermittent docetaxel chemotherapy for hormone refractory prostate cancer].
Olbert PJ; Weil C; Hegele A; Hofmann R; Schrader AJ
Aktuelle Urol; 2009 May; 40(3):164-8. PubMed ID: 19370533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]